热门资讯> 正文
另外，FDA批准开始ReyobiqTM试验后，Thereutics上涨
2025-06-25 21:45
- Shares of Plus Therapeutics (NASDAQ:PSTV) more than doubled after the U.S. FDA cleared the trial initiation for its injectable radiotherapy, Reyobiqtm, to treat pediatric patients with progressive high-grade glioma and ependymoma.
- The trial, known as the ReSPECT-PBC trial, is funded by a $3M research grant from the United States Department of Defense.
- The shares are up 114%.
More on Plus Therapeutics
- Plus Therapeutics, Inc. (PSTV) Q4 2024 Earnings Call Transcript
- Plus Therapeutics drops 5%, files prospectus for 17M share secondary offering
- Plus Therapeutics receives Nasdaq delinquency notice
- Seeking Alpha’s Quant Rating on Plus Therapeutics
- Historical earnings data for Plus Therapeutics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
